Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with
many unique properties such as small size, excellent solubility, superior stability, quick …

As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …

The use of an albumin binder has been shown to improve tumor uptake of prostate-specific
membrane antigen (PSMA)–targeting radiotherapeutic agents. The aim of this study was to …

Purpose Evans blue as an albumin binder has been widely used to improve
pharmacokinetics and enhance tumor uptake of radioligands, including prostate-specific …

Purpose This review discusses the current state of prostate-specific membrane antigen
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …

Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high …

Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for
imaging to assess target expression and, if deemed suitable, for targeted therapy. This …

Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of …